TLDR
- TAO Synergies raised $11 million through a Series E financing agreement.
- James Altucher, TAO Synergies’ advisor, participated in the funding round.
- The deal supports TAO Synergies’ growing position in the Bittensor ecosystem.
- TAO Synergies’ stock surged 38.5% after announcing the $11 million funding.
TAO Synergies, a firm focused on the Bittensor ecosystem, has secured $11 million in private financing. The company entered into a securities purchase agreement that involves the sale of 11,000 shares of its newly issued Series E convertible preferred stock. This financing will support the firm’s ongoing strategic investments in Bittensor tokens and other related revenue-generating opportunities. The deal also includes participation from existing investors and a new partner, DCG.
Details of the Financing Agreement
TAO Synergies raised the $11 million through a share purchase agreement. The company issued 11,000 shares of Series E convertible preferred stock, each valued at $1,000. These shares are convertible into common stock at a price of $8 per share. The agreement includes participation from both existing investors and a new investor, Digital Currency Group (DCG).
The deal is expected to close around October 15, 2025, contingent on meeting standard closing requirements. This round of funding is part of TAO Synergies’ ongoing strategy to increase its holdings in the Bittensor ecosystem, particularly in TAO tokens, which are integral to the platform’s AI-based incentive system.
Role of James Altucher in the Financing
James Altucher, the company’s digital asset strategy advisor, is one of the key participants in this financing deal. Altucher commented on the agreement, noting that the funding will enable TAO Synergies to continue its strategic investments in Bittensor tokens and other related projects. The company’s efforts are aimed at both strengthening its position within the Bittensor network and expanding its revenue-generating capabilities.
TAO Synergies has shown a commitment to staking the TAO tokens it acquires, which helps the firm earn rewards from the Bittensor network. This strategy not only provides additional revenue but also enhances the company’s stake in the growing ecosystem.
Recent Market Activity and Stock Performance
Following the announcement of the financing deal, TAO Synergies saw a significant rise in its stock price. On the day the news broke, the company’s stock increased by 38.46%, reaching $9.54 per share. This surge came after markets had closed for the day. Over the past month, the company’s stock price has climbed 60%, reflecting growing investor interest.
TAO Synergies’ market capitalization now stands at $33.27 million. The firm’s stock performance is closely tied to its position as the largest publicly traded holder of Bittensor, with over $18 million in TAO tokens.
The Firm’s Shift Toward Bittensor Strategy
TAO Synergies, formerly known as Synaptogenix, rebranded in June 2025 as part of its shift towards focusing on Bittensor. The company changed its ticker symbol to TAOX to align with its new strategic direction. This pivot represents the company’s transition from a biotech firm to a player in the cryptocurrency and AI sectors.
The firm is actively staking the TAO tokens it holds, generating rewards within the Bittensor ecosystem. This focus on Bittensor is central to the company’s strategy, as it seeks to capitalize on the growing intersection of AI and blockchain technologies. With the recent funding, TAO Synergies is positioned to strengthen its presence within the ecosystem while exploring additional opportunities for growth and profitability.
TAO Synergies continues to make strategic investments to expand its involvement in the Bittensor network and further its development in the broader cryptocurrency and AI landscape.
